Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson's disease.

Zafar F, Valappil RA, Kim S, Johansen KK, Chang ALS, Tetrud JW, Eis PS, Hatchwell E, Langston JW, Dickson DW, Schüle B.

NPJ Parkinsons Dis. 2018 Jun 15;4:18. doi: 10.1038/s41531-018-0054-4. eCollection 2018.

2.

MPTP-induced parkinsonism: an historical case series.

Nonnekes J, Post B, Tetrud JW, Langston JW, Bloem BR.

Lancet Neurol. 2018 Apr;17(4):300-301. doi: 10.1016/S1474-4422(18)30072-3. Epub 2018 Mar 13. No abstract available. Erratum in: Lancet Neurol. 2018 Mar 27;:.

PMID:
29553378
3.

LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System Atrophy.

Lee K, Nguyen KD, Sun C, Liu M, Zafar F, Saetern J, Flierl A, Tetrud JW, Langston JW, Dickson D, Schüle B.

J Parkinsons Dis. 2018;8(1):93-100. doi: 10.3233/JPD-171237.

PMID:
29480226
4.

Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease.

Tetrud J, Nausieda P, Kreitzman D, Liang GS, Nieves A, Duker AP, Hauser RA, Farbman ES, Ellenbogen A, Hsu A, Kell S, Khanna S, Rubens R, Gupta S.

J Neurol Sci. 2017 Feb 15;373:116-123. doi: 10.1016/j.jns.2016.11.047. Epub 2016 Nov 23.

5.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
6.

Mitochondrial dysfunction in skin fibroblasts from a Parkinson's disease patient with an alpha-synuclein triplication.

Mak SK, Tewari D, Tetrud JW, Langston JW, Schüle B.

J Parkinsons Dis. 2011;1(2):175-83. doi: 10.3233/JPD-2011-11025.

PMID:
23934919
7.

Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease.

Ondo WG, Hunter C, Isaacson SH, Silver DE, Stewart RM, Tetrud JW, Davidson A.

Parkinsonism Relat Disord. 2011 Feb;17(2):117-8. doi: 10.1016/j.parkreldis.2010.10.001. Epub 2010 Nov 16.

PMID:
21084213
8.

Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.

Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R.

Clin Neuropharmacol. 2010 Jan-Feb;33(1):5-10. doi: 10.1097/WNF.0b013e3181b7926f.

PMID:
19855267
9.

Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.

Addy C, Assaid C, Hreniuk D, Stroh M, Xu Y, Herring WJ, Ellenbogen A, Jinnah HA, Kirby L, Leibowitz MT, Stewart RM, Tarsy D, Tetrud J, Stoch SA, Gottesdiener K, Wagner J.

J Clin Pharmacol. 2009 Jul;49(7):856-64. doi: 10.1177/0091270009336735. Epub 2009 Jun 2.

PMID:
19491335
10.

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, Sussman NM; 6002-US-005 Study Group.

Ann Neurol. 2008 Mar;63(3):295-302. doi: 10.1002/ana.21315.

PMID:
18306243
11.
12.

Novel features in a patient homozygous for the L347P mutation in the PINK1 gene.

Doostzadeh J, Tetrud JW, Allen-Auerbach M, Langston JW, Schüle B.

Parkinsonism Relat Disord. 2007 Aug;13(6):359-61. Epub 2006 Oct 19.

PMID:
17055324
13.

Neurodegenerative disorders mimicking progressive supranuclear palsy: a report of three cases.

Murphy MA, Friedman JH, Tetrud JW, Factor SA.

J Clin Neurosci. 2005 Nov;12(8):941-5. Epub 2005 Nov 9.

PMID:
16289932
14.

Treatment challenges in early stage Parkinson's disease.

Tetrud J.

Neurol Clin. 2004 Oct;22(3 Suppl):S19-33. Review. No abstract available.

PMID:
15501364
15.

A novel formulation of selegiline for the treatment of Parkinson's disease.

Tetrud JW, Koller WC.

Neurology. 2004 Oct 12;63(7 Suppl 2):S2-6. Review. No abstract available.

PMID:
15477582
16.

Rest tremor in rhesus monkeys with MPTP-induced parkinsonism.

Emborg ME, Tetrud JW, Moirano J, McLaughlin WW, Bankiewicz KS.

Front Biosci. 2003 May 1;8:a148-54.

PMID:
12700090
17.

Voluntarily simulated tremor in normal subjects.

Burkhard PR, Langston JW, Tetrud JW.

Neurophysiol Clin. 2002 Apr;32(2):119-26.

PMID:
12035489
18.

Essential tremor in twins: an assessment of genetic vs environmental determinants of etiology.

Tanner CM, Goldman SM, Lyons KE, Aston DA, Tetrud JW, Welsh MD, Langston JW, Koller WC.

Neurology. 2001 Oct 23;57(8):1389-91.

PMID:
11673577
19.

An impairment in sniffing contributes to the olfactory impairment in Parkinson's disease.

Sobel N, Thomason ME, Stappen I, Tanner CM, Tetrud JW, Bower JM, Sullivan EV, Gabrieli JD.

Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4154-9. Epub 2001 Mar 20.

20.

The long-term safety and efficacy of pramipexole in advanced Parkinson's disease.

Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, Shulman LM, Glassman PM, Beck B, Paume D, Doyle C.

Parkinsonism Relat Disord. 2001 Apr;7(2):115-120.

PMID:
11248592
21.

A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease.

Shoulson I, Penney J, McDermott M, Schwid S, Kayson E, Chase T, Fahn S, Greenamyre JT, Lang A, Siderowf A, Pearson N, Harrison M, Rost E, Colcher A, Lloyd M, Matthews M, Pahwa R, McGuire D, Lew MF, Schuman S, Marek K, Broshjeit S, Factor S, Brown D, Feigin A, Mazurkiewicz J, Ford B, Jennings D, Dilllon S, Comella C, Blasucci L, Janko K, Shulman L, Wiener W, Bateman-Rodriguez D, Carrion A, Suchowersky O, Lafontaine AL, Pantella C, Siemers E, Belden J, Davies R, Lannon M, Grimes D, Gray P, Martin W, Kennedy L, Adler C, Newman S, Hammerstad J, Stone C, Lewitt P, Bardram K, Mistura K, Miyasaki J, Johnston L, Cha JH, Tennis M, Panniset M, Hall J, Tetrud J, Friedlander J, Hauser R, Gauger L, Rodnitzky R, Deleo A, Dobson J, Seeberger L, Dingmann C, Tarsy D, Ryan P, Elmer L, Ruzicka D, Stacy M, Brewer M, Locke B, Baker D, Casaceli C, Day D, Florack M, Hodgeman K, Laroia N, Nobel R, Orme C, Rexo L, Rothenburgh K, Sulimowicz K, Watts A, Wratni E, Tariot P, Cox C, Leventhal C, Alderfer V, Craun AM, Frey J, McCree L, McDermott J, Cooper J, Holdich T, Read B; Parkinson Study Group.

Neurology. 2001 Feb 27;56(4):455-62.

PMID:
11222787
22.

Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism.

Snow BJ, Vingerhoets FJ, Langston JW, Tetrud JW, Sossi V, Calne DB.

J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):313-6.

23.

Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure.

Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D.

Ann Neurol. 1999 Oct;46(4):598-605.

PMID:
10514096
24.

Quantification of dyskinesia in Parkinson's disease: validation of a novel instrumental method.

Burkhard PR, Shale H, Langston JW, Tetrud JW.

Mov Disord. 1999 Sep;14(5):754-63.

PMID:
10495036
25.

Autopsy-proven progressive supranuclear palsy in two siblings.

Tetrud JW, Golbe LI, Forno LS, Farmer PM.

Neurology. 1996 Apr;46(4):931-4.

PMID:
8780066
26.

Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions.

Vingerhoets FJ, Snow BJ, Tetrud JW, Langston JW, Schulzer M, Calne DB.

Ann Neurol. 1994 Nov;36(5):765-70.

PMID:
7979223
27.

Parkinsonism caused by petroleum waste ingestion.

Tetrud JW, Langston JW, Irwin I, Snow B.

Neurology. 1994 Jun;44(6):1051-4.

PMID:
8208398
28.

Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.

Kurth MC, Tetrud JW, Tanner CM, Irwin I, Stebbins GT, Goetz CG, Langston JW.

Neurology. 1993 Sep;43(9):1698-703.

PMID:
8414015
29.

Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study.

Kurth MC, Tetrud JW, Irwin I, Lyness WH, Langston JW.

Neurology. 1993 May;43(5):1036-9.

PMID:
8492922
30.

Fifteen months' follow-up on bilateral embryonic mesencephalic grafts in two cases of severe MPTP-induced parkinsonism.

Widner H, Tetrud J, Rehncrona S, Snow BJ, Brundin P, Björklund A, Lindvall O, Langston JW.

Adv Neurol. 1993;60:729-33. No abstract available.

PMID:
8420218
31.

Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B, Björklund A, Lindvall O, Langston JW.

N Engl J Med. 1992 Nov 26;327(22):1556-63.

32.

Lack of major olfactory dysfunction in MPTP-induced parkinsonism.

Doty RL, Singh A, Tetrud J, Langston JW.

Ann Neurol. 1992 Jul;32(1):97-100.

PMID:
1642478
33.

Protective and preventive therapeutic strategies: monoamine oxidase inhibitors.

Tetrud JW, Langston JW.

Neurol Clin. 1992 May;10(2):541-52. Review.

PMID:
1584188
34.

Tremor in MPTP-induced parkinsonism.

Tetrud JW, Langston JW.

Neurology. 1992 Feb;42(2):407-10.

PMID:
1736174
35.

Preclinical detection of motor and nonmotor manifestations.

Tetrud JW.

Geriatrics. 1991 Aug;46 Suppl 1:43-6.

PMID:
1894144
36.

An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients.

Olanow CW, Nakano K, Nausieda P, Tetrud JA, Manyam B, Last B, Block G, Liss C, Bush D.

Clin Neuropharmacol. 1991 Jun;14(3):235-40.

PMID:
2070363
37.

Preclinical Parkinson's disease: detection of motor and nonmotor manifestations.

Tetrud JW.

Neurology. 1991 May;41(5 Suppl 2):69-71; discussion 72.

PMID:
2041596
38.

Blood lactate in Parkinson's disease.

Di Monte D, Tetrud JW, Langston JW.

Ann Neurol. 1991 Mar;29(3):342-3. No abstract available.

PMID:
2042953
39.

"Stelazine" versus "selegiline"--a hazard in prescription writing.

Kurth MC, Langston JW, Tetrud JW.

N Engl J Med. 1990 Dec 20;323(25):1776. No abstract available.

PMID:
2123299
40.

The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease.

Bloem BR, Irwin I, Buruma OJ, Haan J, Roos RA, Tetrud JW, Langston JW.

J Neurol Sci. 1990 Jul;97(2-3):273-93. Review.

PMID:
2205710
41.

Cognitive change following MPTP exposure.

Stern Y, Tetrud JW, Martin WR, Kutner SJ, Langston JW.

Neurology. 1990 Feb;40(2):261-4.

PMID:
2300245
42.

Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Tetrud JW, Langston JW, Garbe PL, Ruttenber AJ.

Neurology. 1989 Nov;39(11):1483-7.

PMID:
2812327
43.

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

Tetrud JW, Langston JW.

Science. 1989 Aug 4;245(4917):519-22.

PMID:
2502843
44.

MPTP-induced parkinsonism as a model for Parkinson's disease.

Tetrud JW, Langston JW.

Acta Neurol Scand Suppl. 1989;126:35-40. Review.

PMID:
2694734
45.

R-(-)-deprenyl as a possible protective agent in Parkinson's disease.

Tetrud JW, Langston JW.

J Neural Transm Suppl. 1987;25:69-79.

PMID:
3123606
46.

Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.

Ballard PA, Tetrud JW, Langston JW.

Neurology. 1985 Jul;35(7):949-56.

PMID:
3874373
47.

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

Langston JW, Ballard P, Tetrud JW, Irwin I.

Science. 1983 Feb 25;219(4587):979-80.

PMID:
6823561
48.

Pseudo-ileovesical fistula in Crohn disease.

Panitch NM, Henn RM, Tetrud JW.

JAMA. 1975 May 19;232(7):732-3. No abstract available.

PMID:
1173172
49.

Design of an analog converter for use in colorimetry.

Lapidus BM, Tetrud JW, Karmen A.

Clin Chem. 1971 Mar;17(3):231-2. No abstract available.

Supplemental Content

Loading ...
Support Center